Drug Topics
OCTOBER 21, 2024
Researchers explored the overall efficacy of various pediatric vaccines and their effects on antibiotic use, while also addressing vaccine hesitancy among parents.
STAT
OCTOBER 21, 2024
If you were hoping to see where ultra-processed foods might fit in the next Dietary Guidelines for Americans, hold that thought. Scientific experts tasked with advising federal officials drafting the 2025-2030 Dietary Guidelines for Americans said the data were far too limited to draw conclusions. Meeting Monday, the first of two days of presentations, they discussed research findings to inform a report to the Department of Health and Human Services and the Department of Agriculture.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
OCTOBER 21, 2024
Researchers explored the stigmatization of sexually transmitted infections across film while also identifying inaccuracies in STI-related content on Tik Tok.
STAT
OCTOBER 21, 2024
Confounding data from a Pfizer clinical trial has rattled the field of gene therapy for Duchenne muscular dystrophy, raising more questions about the regulatory standard used to approve a treatment from Sarepta Therapeutics, and complicating plans for other companies hoping to develop next-generation products. Scientifically, Pfizer’s gene therapy did what it was supposed to do.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
OCTOBER 21, 2024
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too. | As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too.
STAT
OCTOBER 21, 2024
STAT is publishing this investigation in partnership with The Examination. Perham Gorji was a career government lawyer, helping to lead the Food and Drug Administration’s battle against tobacco and e-cigarettes. He was there as the agency contemplated a ban on menthol cigarettes, and as vapes of all shapes and sizes flooded the market, hooking a new generation on nicotine.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
OCTOBER 21, 2024
It began with a burning pain in her right eye. At first, Elisabeth Cohen thought she’d gotten something in it. But the next day, as she was pushing her hair back on that side of her head, she noticed a blister near the hairline. She knew immediately what it was: shingles. At the time, in 2008, Cohen was director of the Cornea Service at Wills Eye Hospital in Philadelphia.
Pharmacy Times
OCTOBER 21, 2024
A dedicated community pharmacist for over 40 years, Kessler has witnessed immense change and innovation throughout his career.
STAT
OCTOBER 21, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. The ‘#1 PRIORITY’ The emails from inside a physician practice owned by UnitedHealth Group sounded cheery, but were all business.
Drug Topics
OCTOBER 21, 2024
Opioid use disorder risk was higher in a cohort of patients with chronic pain without disability.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
OCTOBER 21, 2024
A coalition of 12 Philadelphia-area health systems announced Monday that its members have abandoned the use of race adjustments in four clinical tools commonly used to guide care, a move that health leaders say will improve treatment and prevent delays in diagnosis for Black, Hispanic, and Asian patients. The decision marks one of the largest and broadest efforts to date to remove race from widely used clinical algorithms.
pharmaphorum
OCTOBER 21, 2024
A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African American, Black, Hispanic and Latino, plugging a gap in the data for the drug.Vabysmo (faricimab) has been approved by the FDA for treating DME since 2022, quickly becoming one of the Swiss pharma group's fastest-growing products with sales of $1.1 billion in the first half of the year.
STAT
OCTOBER 21, 2024
Does it make sense for a chain of drug stores to own a major health insurance company? That has been the existential question for CVS Health for six years, since its $70 billion acquisition of the massive insurer Aetna. The biggest pharmacy chain in the U.S. had already been moving beyond retail since its 2007 deal for pharmacy benefit manager Caremark.
pharmaphorum
OCTOBER 21, 2024
Seaport Therapeutics completes a $225m Series B to fund its improved therapies for depression and anxiety, just months after raising $100m on its debut
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
OCTOBER 21, 2024
I have lost babies. Well, I didn’t lose them per se. They haven’t been misplaced, like keys or something. To forgo the polite euphemisms, they died after 20 weeks. I felt isolated, devastated, and like there wasn’t a vocabulary for what happened — clinically, emotionally, or legally.
Fierce Healthcare
OCTOBER 21, 2024
LAS VEGAS—A new partnership aims to make it simpler for plans to integrate ancillary benefits such as transportation for health-related social needs and grocery delivery into their packages. | A new partnership aims to make it simpler for plans to integrate ancillary benefits such as transportation for health-related social needs and grocery delivery into their packages.
STAT
OCTOBER 21, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Have you ever seen an award-winning journalist sing karaoke? After the Summit ended last week, a big group of STAT staffers belted and crooned together for hours and my heart has never been so full. It was all deeply off the record so I can’t tell you who sang what.
Fierce Healthcare
OCTOBER 21, 2024
LAS VEGAS—Recursion and Google Cloud have expanded their tech partnership to use cloud technologies to power Rcursion's drug discovery platform. | On the second day of HLTH, Recursion announced it was deepening its partnership with Google Cloud and HealthEx unveiled a $14 million funding round.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Topics
OCTOBER 21, 2024
Suzetrigine could represent the first new nonopioid drug in a distinct class of pain medications in approximately 20 years.
STAT
OCTOBER 21, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so familiar routine of online meetings, calls, and deadlines has predictably returned. To cope, we are firing up the coffee kettle in the Pharmalot cafeteria and brewing another cup of stimulation. Our choice today is the seasonal pumpkin spice.
Pharmacy Times
OCTOBER 21, 2024
The story of pinksocks and the inspiring movement that they launched.
pharmaphorum
OCTOBER 21, 2024
Two digital therapeutics for addiction are available again through PursueCare, which acquired them from now-defunct Pear Tx last year
Fierce Healthcare
OCTOBER 21, 2024
Academic health system Cleveland Clinic is teaming up with an industry disruptor to expand primary care services in Northeast Ohio. | Academic health system Cleveland Clinic is teaming up with an industry disruptor to expand primary care services in Northeast Ohio.
PharmaVoice
OCTOBER 21, 2024
Providers struggle with time-consuming processes. Patients are waiting for therapy. Embedded EMR system solutions can streamline therapy initiation and improve outcomes.
STAT
OCTOBER 21, 2024
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Morning! Today, we discuss why disappointing data from Pfizer’s Duchenne muscular dystrophy trial might spell trouble for others developing gene therapies for the condition.
pharmaphorum
OCTOBER 21, 2024
Novo Nordisk's TFPI drug concizumab has been backed for approval in the EU to prevent bleeding episodes in people with haemophilia and inhibitors
Fierce Healthcare
OCTOBER 21, 2024
LAS VEGAS—Health tech companies CopilotIQ and Biofourmis announced a strategic merger on Monday that combines tech-enabled in-home care solutions from pre-surgical optimization to acute, post-acute | Health tech companies CopilotIQ and Biofourmis announced a strategic merger on Monday that combines tech-enabled in-home care solutions from pre-surgical optimization to acute, post-acute and chronic care.
STAT
OCTOBER 21, 2024
Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s parent — will not raise competitive concerns or diminish its ability to provide services to other drug companies. Catalent is an attractive buyout target for Novo Holdings — which owns 77% of the voting shares in the drugmaker — because it is currently a subcontractor that
Fierce Healthcare
OCTOBER 21, 2024
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster protections around birth control and other preventive services. | The U.S. federal government is attempting to ease access to birth control products and HIV prevention drugs in a newly proposed rule.
Pharmacy Times
OCTOBER 21, 2024
Non–FDA-approved medications may be accessed for patient care via 3 alternative pathways: expanded access, the Right to Try Act, and off-label use, which are reviewed in this article.
Fierce Pharma
OCTOBER 21, 2024
Sanofi is now in “exclusive negotiations” with U.S. | Sanofi is now in “exclusive negotiations" with U.S. private equity firm Clayton, Dubilier & Rice to sell a 50% controlling stake in its consumer health business Opella, the company said. The deal values the consumer group at 16 billion euros.
Pharmacy Times
OCTOBER 21, 2024
The implementation of accountable care organizations (ACOs) also worsened disparities in any emergency department or hospital use for Medicaid-insured children with asthma.
Fierce Pharma
OCTOBER 21, 2024
Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has Johnson & Johnson’s consumer health spinout Kenvue in its sights. | Starboard, which recently pitched turnaround plans to Pfizer, reportedly thinks the J&J consumer health spinout's stocks have underperformed since its market debut over a year ago.
Expert insights. Personalized for you.
201 
Let's personalize your content